C4 Therapeutics director granted 62,000 stock options

C4 Therapeutics director Ronald Harold Wilfred Cooper received a grant of stock options covering 62,000 shares of common stock.

Rhea-AI Filing Summary

C4 Therapeutics director Ronald Harold Wilfred Cooper received a grant of stock options covering 62,000 shares of common stock. The options have an exercise price of $4.25 per share and were awarded at no cost to him.

These options vest and become fully exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, as long as he continues serving on the board through that date. After this grant, his reported holdings of this option award total 62,000 derivative securities.

Insider Trade Summary

Grant/Award: 62,000 shares

Grant/Award 1 txn

Insider Cooper Ronald Harold Wilfred

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	62,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 62,000 contracts (Direct)

Footnotes (1)

1. F1. This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Key Figures

Option grant size: 62,000 options Exercise price: $4.25 per share Post-transaction derivative holdings: 62,000 derivative securities +2 more

5 metrics

Option grant size 62,000 options Stock Option (Right to Buy) grant on June 24, 2026

Exercise price $4.25 per share Exercise price of stock option grant

Post-transaction derivative holdings 62,000 derivative securities Total options held following transaction

Vesting date trigger June 24, 2027 Latest date when options vest in full if still serving

Expiration date June 23, 2036 Option expiration date for the award

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, derivative securities, exercise price, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

derivative securities financial

"derivativeTransactionCount: 1, indicating derivative securities activity"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

exercise price financial

"conversion_or_exercise_price: "4.2500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did C4 Therapeutics (CCCC) report for Ronald Cooper?

C4 Therapeutics reported that director Ronald Harold Wilfred Cooper received a grant of stock options for 62,000 shares of common stock. The award was recorded as a derivative acquisition under code A, reflecting a grant or other award rather than an open-market purchase.

What is the exercise price and size of Ronald Cooper’s new C4 Therapeutics options?

Ronald Cooper received stock options covering 62,000 shares of C4 Therapeutics common stock at an exercise price of $4.25 per share. The filing shows this entire amount as held following the transaction, tied to a single option award reported on the same date.

When do Ronald Cooper’s newly granted C4 Therapeutics options vest?

The options vest and become exercisable in full on the earlier of June 24, 2027 or the next annual meeting of C4 Therapeutics stockholders. Vesting is conditioned on his continued service as a member of the board through that vesting date, according to the footnote.

Is Ronald Cooper’s C4 Therapeutics option grant an open-market purchase or a compensation award?

The transaction is a compensation-related award, not an open-market purchase. It is coded “A” for grant, award, or other acquisition, with a zero-dollar transaction price and a specified $4.25 exercise price for future potential share purchases.

How many C4 Therapeutics derivative securities does Ronald Cooper hold after this Form 4 transaction?

Following the reported transaction, Ronald Cooper holds 62,000 derivative securities linked to C4 Therapeutics common stock. This amount matches the size of the stock option grant reported, indicating the full award is reflected as held after the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 04:29 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cooper Ronald Harold Wilfred

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.25	06/24/2026		A		62,000		(1)	06/23/2036	Common Stock	62,000	$0	62,000	D

Explanation of Responses:

1. This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)